# OnCo record nct04590326 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04590326/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04590326", "NCT04590326" ;
  schema:name "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata"@en ;
  schema:description "A phase 1/2 trial of Cemiplimab in ovarian cancer and endometrial cancer, run by Regeneron Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04590326/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04590326> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2020-12-08" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/regeneron/> .